OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
960457

Miral Dental Clinics Company SCJSC

Healthcare Facilities & ServicesVerified

Miral Dental Clinics maintains a strong liquidity position, with a current ratio of 5.5, indicating that current assets significantly exceed current liabilities. The company holds SAR 18.1 million in cash and equivalents, supporting its short-term obligations and operational flexibility. The debt-to-equity ratio of 0.21 suggests a conservative capital structure, with long-term debt accounting for a small portion of total equity. This low leverage supports financial stability and reduces interest burden risk. Profitability metrics highlight the company's strong performance, with a return on equity (ROE) of 23.65% and a return on assets (ROA) of 17.15%. These figures exceed typical benchmarks for the Healthcare Facilities & Services industry, indicating efficient use of equity and asset base to generate returns. Gross profit of SAR 30.4 million and operating income of SAR 18.9 million reflect strong pricing power and cost control in a competitive market. The company's revenue is concentrated in two branches in Riyadh, with no disclosed geographic diversification. This concentration increases exposure to local economic conditions and regulatory changes in Saudi Arabia. While the company's services are essential, the lack of geographic expansion limits growth potential and resilience to regional shocks. Growth trajectory appears stable, with revenue of SAR 83.0 million in the latest period. While no forward-looking guidance is provided, the company's operating cash flow of SAR 25.3 million and free cash flow of SAR 17.8 million support reinvestment and potential expansion. Capital expenditures of SAR 7.4 million suggest ongoing investment in infrastructure, though the scale is modest relative to total assets. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong cash reserves reduce refinancing and interest rate exposure. No dilution pressure is evident from recent filings or capital structure, and the number of shares outstanding remains unchanged between basic and diluted measures. Recent filings and transcripts do not disclose material events or strategic shifts. The company's operations remain focused on its core dental services in Riyadh, with no announced expansion or diversification plans. This stability supports predictability but may limit upside potential in a rapidly evolving healthcare market.

30-day price · 9604-2.90 (-2.8%)
Low$100.00High$106.00Close$100.10As of17 May, 00:00 UTC
Profile
CompanyMiral Dental Clinics Company SCJSC
Ticker9604.SE
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Miral Dental Clinics Company SCJSC operates dental, treatment, and cosmetic services through two branches in Riyadh, Saudi Arabia, generating revenue primarily from outpatient dental care and related procedures.

Classification. Miral Dental Clinics is classified under the Healthcare Facilities & Services industry within the Healthcare Services & Equipment business sector, with a confidence level of 0.92 based on verified market data.

Miral Dental Clinics maintains a strong liquidity position, with a current ratio of 5.5, indicating that current assets significantly exceed current liabilities. The company holds SAR 18.1 million in cash and equivalents, supporting its short-term obligations and operational flexibility. The debt-to-equity ratio of 0.21 suggests a conservative capital structure, with long-term debt accounting for a small portion of total equity. This low leverage supports financial stability and reduces interest burden risk. Profitability metrics highlight the company's strong performance, with a return on equity (ROE) of 23.65% and a return on assets (ROA) of 17.15%. These figures exceed typical benchmarks for the Healthcare Facilities & Services industry, indicating efficient use of equity and asset base to generate returns. Gross profit of SAR 30.4 million and operating income of SAR 18.9 million reflect strong pricing power and cost control in a competitive market. The company's revenue is concentrated in two branches in Riyadh, with no disclosed geographic diversification. This concentration increases exposure to local economic conditions and regulatory changes in Saudi Arabia. While the company's services are essential, the lack of geographic expansion limits growth potential and resilience to regional shocks. Growth trajectory appears stable, with revenue of SAR 83.0 million in the latest period. While no forward-looking guidance is provided, the company's operating cash flow of SAR 25.3 million and free cash flow of SAR 17.8 million support reinvestment and potential expansion. Capital expenditures of SAR 7.4 million suggest ongoing investment in infrastructure, though the scale is modest relative to total assets. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong cash reserves reduce refinancing and interest rate exposure. No dilution pressure is evident from recent filings or capital structure, and the number of shares outstanding remains unchanged between basic and diluted measures. Recent filings and transcripts do not disclose material events or strategic shifts. The company's operations remain focused on its core dental services in Riyadh, with no announced expansion or diversification plans. This stability supports predictability but may limit upside potential in a rapidly evolving healthcare market.
Key takeaways
  • Strong liquidity and conservative leverage support financial stability.
  • High ROE and ROA reflect efficient asset and equity utilization.
  • Revenue concentration in two Riyadh branches increases regional risk.
  • No immediate dilution or liquidity risks identified.
  • Modest capital expenditures suggest limited near-term growth investment.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySAR
Revenue$83.0M
Gross profit$30.4M
Operating income$18.9M
Net income$18.4M
R&D
SG&A
D&A
SBC
Operating cash flow$25.3M
CapEx-$7.4M
Free cash flow$17.8M
Total assets$107.2M
Total liabilities$29.4M
Total equity$77.8M
Cash & equivalents$18.1M
Long-term debt$15.9M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$77.8M
Net cash$2.2M
Current ratio5.5
Debt/Equity0.2
ROA17.2%
ROE23.6%
Cash conversion1.4%
CapEx/Revenue-8.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
Metric9604Activity
Op margin22.8%11.5% medp25 9.9% · p75 15.0%top quartile
Net margin22.1%8.6% medp25 6.3% · p75 12.4%top quartile
Gross margin36.6%28.8% medp25 28.8% · p75 28.8%top quartile
CapEx / revenue-8.9%4.2% medp25 3.8% · p75 4.2%bottom quartile
Debt / equity21.0%71.3% medp25 60.7% · p75 71.3%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 03:12 UTC#5b841999
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 03:14 UTCJob: bda01b9f